Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27929797 | 0.79 | ACHE (0.34) | GAAHPGDRECQLHRH3 | |
| SCHEMBL489224 | 0.76 | LMNA (0.34) | GAAHPGDRECQLHRH3 | |
| SCHEMBL6392087 | 0.76 | LMNA (0.34) | GAAHPGDRECQLHRH3 | |
| SCHEMBL120892 | 0.76 | LMNA (0.34) | GAAHPGDRECQLHRH3 | |
| SCHEMBL27892417 | 0.74 | ENO1 (0.34) | GAAHPGDRECQLHRH3 | |
| SCHEMBL27517307 | 0.73 | HPGD (0.41) | GAAHPGDRECQL | |
| SCHEMBL28780419 | 0.73 | POLB (0.33) | GAAHPGDRECQLHRH3 | |
| SCHEMBL8455130 | 0.71 | HPGD (0.36) | HPGDHRH3 | |
| SCHEMBL489632 | 0.70 | GAA (0.39) | GAAHPGDRECQL | |
| SCHEMBL2807972 | 0.70 | TSHR (0.35) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133891-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7968540-B2 | Spirohydantoin tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7947677-B2 | Spirolactam tricyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7750010-B2 | Tricyclic anilide spirohydantion CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| US-7696192-B2 | Tricyclic anilide spirolactam CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-11-12 | — | — | US | disclosed |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | MERCK SHARP & DOHME LLC | 2009-09-03 | — | — | US | disclosed |
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | MERCK & CO., INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214511-A1 | Tricyclic Anilide Spirolactam Cgrp Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | GAA 3809/4885HPGD 692/4885RECQL 1008/4885 |
| US-20100160334-A1 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, CALCRL, BDKRB2 | GAA 3809/4885HPGD 692/4885RECQL 1008/4885 |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | GAA 2768/4885HPGD 502/4885RECQL 756/4885 |
| US-20090105219-A1 | Spirolactam Tricyclic CGRP Receptor Antagonists | BDKRB1, CALCRL, BDKRB2 | GAA 3125/4885HPGD 529/4885RECQL 600/4885 |
| US-20090281080-A1 | Spirohydantoin Tricyclic CGRP Receptor Antagonists | BDKRB1, BDKRB2, CCKBR | GAA 3522/4885HPGD 384/4885RECQL 375/4885 |
| US-20090221535-A1 | IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA SUCH AS STREPTOCOCCUS AGALACTIAE | C1R, CALCB, MRGPRX2 | GAA 1576/4885HPGD 1480/4885RECQL 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.